Phase 4 Study Accessing Patient Satisfaction and Tear Osmolarity While Using Blink Tears, Blink Gel Tears and Systane Balance
Sponsor study identifier
observational
60
1 country
1
Study Start
May 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This is a single center clinical study designed to determine patient satisfaction and the effect of the use of artificial tears on tear osmolarity with time after instillation of three commercially available artifical tear eye solutions ( Blink Tears, Blink Gel Tears and Systane Balance).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 30, 2012
Actual (reported)May 2012
Date type not reportedThis date has not been verified as actual or estimated.
May 2, 2012
Actual (reported)September 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary efficacy variable is tear osmolarity
28 days
Secondary efficacy variable is the Patient Symptom Questionnaire
28 days
Blink Tears is an over the counter artificial tear
Blink Gel Tears is an over the counter artifical tear product
Systane Balance is an over the counter artificial Tear product
2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
greater then age 18
Ophthalmic Consultants of Connecticut
Fairfield, Connecticut, 06824, United States
Eric Donnenfeld, M.D.
Ophthalmic Consultants of Connecticut
First Submitted
April 30, 2012
First Posted
May 2, 2012
Study Start
May 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2012
Estimated (date passed)2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 2, 2012
Record last verified: 2012-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: